Clinical Trial Update: Oral Administration or Nasal Feeding of Huzhangxiefei Decoction for Treatment in Sepsis Induced Acute Lung Injury [Phase 2]

View source ↗

Summary

Phase 2 trial investigating oral or nasal administration of Huzhangxiefei Decoction for sepsis-induced acute lung injury; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Sepsis

Drugs mentioned

• Huzhangxiefei Decoction

Snippet

Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Acute Lung Injury, Sepsis | Phase 2 | Status: UNKNOWN